ZYUS:CA:TSV-ZYUS Life Sciences Corporation (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1.01

Change

-0.01 (-0.98)%

Market Cap

USD 0.07B

Volume

200.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-19 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

+0.04 (+0.36%)

USD 0.13B
LOVE:CA Cannara Biotech Inc

N/A

USD 0.06B
SBBC:CA Simply Better Brands Corp

-0.03 (-5.00%)

USD 0.05B
LSL:CA LSL Pharma Group Inc.

-0.01 (-1.12%)

USD 0.05B
ROMJ:CA Rubicon Organics Inc

+0.02 (+4.76%)

USD 0.02B
DB:CA Decibel Cannabis Company Inc

N/A

USD 0.02B
PCLO:CA Pharmacielo Ltd

-0.01 (-5.71%)

USD 0.02B
MPH:CA Medicure Inc

N/A

USD 0.01B
CANB:CA CanadaBis Capital Inc

N/A

USD 7.60M
VM:CA Voyageur Pharmaceuticals Ltd

N/A

USD 6.97M

ETFs Containing ZYUS:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.22% 65% D 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.22% 65% D 65% D
Trailing 12 Months  
Capital Gain -45.99% 32% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.99% 32% F 31% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.07B 95% A 89% A-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.